Speakers > Dr. Jason J. Luke

 

Dr. Jason J. Luke

Dr. Luke is an internationally recognized investigator in developmental cancer therapeutics, particularly immunotherapies, where he has led clinical trials ranging from the Phase III Keynote-716 trial of pembrolizumab in stage II melanoma to Phase I studies of novel therapeutics covering checkpoint inhibitors, innate immune stimulators, adoptive cell transfer and immuno-metabolism approaches, among others. Dr. Luke received his M.D. from the Rosalind Franklin University of Medicine and Science and then trained at Boston University Medical Center and Memorial-Sloan-Kettering Cancer Center. He subsequently has held faculty positions at Dana-Farber Cancer Institute, the University of Chicago and currently the University of Pittsburgh. Dr. Luke’s translational research is focused on application of large-scale informatics to advance cancer immunotherapy and he has been a lead investigator for clinical trials of numerous novel immunotherapy agents. Dr. Luke has received research support and/or professional awards from the NCI, DOD, ASCO and multiple professional or private societies.